[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370319-105":59,"doc-detail-370319-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sf3b1-from-core-splicing-factor-to-oncogenic-driver-review","SF3B1 - from core splicing factor to oncogenic driver - review","","Highly recurrent somatic mutations in the SF3B1 core splicing factor gene act as drivers across multiple cancer types. SF3B1 is a scaffold protein that coordinates multivalent protein interactions within the spliceosome, enabling branchsite recognition and 3′ splice-site selection during early pre-mRNA splicing. The review explains how oncogenic SF3B1 mutations derail splicing by perturbing an early trimeric spliceosomal complex, activating upstream branchpoints and using cryptic 3′ splice sites, then links aberrant transcript changes to cancer initiation and progression. It also emphasizes prognostic and disease-phenotype differences among SF3B1 mutations to guide targeted therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sf3b1-from-core-splicing-factor-to-oncogenic-driver-review/370319/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sf3b1-from-core-splicing-factor-to-oncogenic-driver-review/370319.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does SF3B1 play in normal pre-mRNA splicing?","Question",{"text":112,"@type":113},"SF3B1 is a scaffold protein that organizes multivalent protein–protein interactions within the spliceosome, supporting branchsite (BS) recognition and 3′ splice-site selection at the early pre-mRNA splicing stage.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do oncogenic SF3B1 mutations disrupt splicing?",{"text":117,"@type":113},"They perturb an early trimeric spliceosomal protein complex required for accurate BS recognition in a subset of introns, which activates upstream branchpoints and leads to selection of cryptic 3′ splice sites.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are different SF3B1 mutations important for cancer therapy?",{"text":121,"@type":113},"The review highlights that prognostic value and cancer disease phenotypes vary among SF3B1 mutations, which is critical for developing targeted therapeutics for SF3B1-mutant cancers that still lack effective clinical options.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370319,1790731634,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","SF3B1: from core splicing factor to oncogenic driver  \nPEDRO BAK-GORDON and JAMES L. MANLEY  \nDepartment of Biological Sciences, Columbia University, New York, New York 10027, USA  \nABSTRACT  \nHighly recurrent somatic mutations in the gene encoding the core splicing factor SF3B1 are drivers of multiple cancer types. SF3B1 is a scaffold protein that orchestrates multivalent protein–protein interactions within the spliceosome that are essential for recognizing the branchsite (BS) and selecting the 3′ splice site during the earliest stage of pre-mRNA splicing. In this review, we first describe the molecular mechanism by which multiple oncogenic SF3B1 mutations disrupt splicing. This involves perturbation of an early spliceosomal trimeric protein complex necessary for accurate BS recognition in a subset of introns, which leads to activation of upstream branchpoints and selection of cryptic 3′ splice sites. We next discuss how specific transcripts affected by aberrant splicing in SF3B1-mutant cells contribute to the initiation and progression of cancer. Finally, we highlight the prognostic value and disease phenotypes of different cancer-associated SF3B1 mutations, which is critical for developing new targeted therapeutics against SF3B1-mutant cancers still lacking in the clinic.  \nKeywords: SF3B1; SUGP1; RNA splicing; branchsite; cancer  \nINTRODUCTION  \nRNA splicing is a complex process conserved across eukaryotes by which introns are excised from precursor messenger RNAs (pre-mRNAs) and exons are ligated to form mature mRNA transcripts (Wilkinson et al. 2020; Rogalska et al. 2023) . In multicellular organisms, the combinatorial selection of different intronic and exonic segments through the process of alternative splicing is critical to achieving tissue-specific gene expression that regulates cell differentiation, function, and homeostasis (Baralle and Giudice 2017) . Early RNA-sequencing (RNA-seq) studies revealed that in humans, up to 95% of multiexon transcripts undergo alternative splicing (Pan et al. 2008; Wang et al. 2008), which can contribute to functional protein diversity and phenotypic complexity (Weatheritt et al. 2016; Blencowe 2017; Liu et al. 2017; Reixachs-Solé et al. 2020; Wright et al. 2022; Kjer-Hansen and Weatheritt 2023) . The critical importance of pre-mRNA splicing in regulating cellular behavior has also been confirmed by the observation that splicing dysregulation contributes to human diseases, including cancer (Bonnal et al. 2020; Bradley and Anczuków 2023) . In fact, tumors have up to 30% more alternative splicing than normal cells (Kahles et al. 2018), and 68% of cancer samples have at least one splicing-derived neoepitope (Frankiw et al. 2019) . It is further estimated that up to 50% of all disease-causing mutations affect splicing (Car-  \ntegni et al. 2002; López-Bigas et al. 2005; Wang and Cooper 2007), underscoring the importance of understanding the molecular mechanisms of pathogenic RNA splicing to create opportunities for therapeutic correction (Desterroet al. 2020; Rogalska et al. 2023) .  \nAlterations that affect splicing regulation in cancer can arise in different ways. The simplest type mechanistically is cis-acting mutations that occur in regulatory sequence elements of the pre-mRNA that disrupt normal splicing (Supek et al. 2014; Jung et al. 2015) . Another type is trans-acting mutations in genes encoding spliceosomal proteins (Bejar 2016; Dvinge et al. 2016; Zhang et al. 2024a) or perhaps snRNAs (Shuai et al. 2019), which can also alter splicing patterns. And finally, expression changes of splicing regulators, such as SR or hnRNP proteins, candysregulate alternative splicing patterns of target transcripts (Karni et al. 2007; David et al. 2010; Anczukówet al. 2012) .  \nHighly recurrent somatic mutations in human genes encoding components of the splicing machinery were first described in patients with myelodysplastic syndromes (MDS) (Papaemmanuil et al. 2011; Yoshida et al. 2011; Graubert e","cbCailgGYxhO74sQ","https://ap.wps.com/l/cbCailgGYxhO74sQ","pdf",1207014,"English","# Abstract\n# Introduction\n## RNA splicing as a conserved regulatory process\n## How splicing dysregulation arises in cancer\n## SF3B1 mutations and their link to malignancies","[{\"question\":\"What role does SF3B1 play in normal pre-mRNA splicing?\",\"answer\":\"SF3B1 is a scaffold protein that organizes multivalent protein–protein interactions within the spliceosome, supporting branchsite (BS) recognition and 3′ splice-site selection at the early pre-mRNA splicing stage.\"},{\"question\":\"How do oncogenic SF3B1 mutations disrupt splicing?\",\"answer\":\"They perturb an early trimeric spliceosomal protein complex required for accurate BS recognition in a subset of introns, which activates upstream branchpoints and leads to selection of cryptic 3′ splice sites.\"},{\"question\":\"Why are different SF3B1 mutations important for cancer therapy?\",\"answer\":\"The review highlights that prognostic value and cancer disease phenotypes vary among SF3B1 mutations, which is critical for developing targeted therapeutics for SF3B1-mutant cancers that still lack effective clinical options.\"}]","SF3B1 - from core splicing factor to oncogenic driver - review | PDF",1790187967,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2929ecb6b81191ad6e820d7fbe46472a.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce99cfa1179c11adb4d9aea47a8af79c.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03f5a34fc69642a92b3a8640fbf379ff.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee1389e99db2a19c63d32f65fda49cf5.webp",980,1268]